|

Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery

RECRUITINGSponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Actively Recruiting
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
Started2024-03-01
Est. completion2026-03
Eligibility
Age18 Years – 85 Years

Summary

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of early-stage lung cancer patients who have received surgery using the real-world data. The main questions it aims to answer are: * What is the best surgical strategy for patients with early-stage lung cancer? * What are the risk factors for early-stage lung cancer? Participants will receive surgery and the study will analyze the real-world data.

Eligibility

Age: 18 Years – 85 Years
Inclusion Criteria:

1. Aged between 18 and 85;
2. Did not receive neoadjuvant therapy before surgery;
3. No history of radiation therapy;
4. Eastern Cooperative Oncology Group (ECOG) score is 0-1;
5. Have complete clinically relevant information including imaging data;
6. All patients underwent relevant preoperative examinations;
7. Stage I lung cancer (International Association for the Study of Lung Cancer/The Union for International Cancer Control staging eighth edition);

Exclusion Criteria:

1. Have previously received chemotherapy, radiotherapy and other anti-tumor therapy;
2. Data loss and error in medical records due to human/objective reasons.

Conditions2

CancerLung Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.